1McMurray J, Solomon S, Pieper K, et al. The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction : an anal- ysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). J Am Coll Cardiol,2006,47:726-733.
2Ouzounian M, Hassan A, Cox JL, et al. The effect of spironolactone use on heart failure mortality: a population-based study. J Card Fail,2007,13: 165-169.
3Khouri SJ, Maly GT, Suh DD, et al. A practical approach to the echocar- diographic evaluation of diastolic function. J Am Soc Echocardiogr,2004, 17 : 290-297.
4Modena MG, Aveta P, Menozzi A, et al. Aldosterone inhibition limits colla- gen synthesis and progressive left ventricular enlargement after anterior my- ocardial infarction. Am Heart J,2001,141:41-46.
5Prasad A, Popovic ZB, Arbab-Zadeh A, et al. The effects of aging and physical activity on Doppler measures of diastolic function. Am J Cardiol, 2007,99 : 1629-1636.
6Wang J, Khoury DS,Thohan V, et al. Global diastolic strain rate for the as- sessment of left ventricular relaxation and filling pressures. Circulation, 2007,115 : 1376-1383.
7Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioac- tivity,improves endothelial vasodilator dysfunction, and suppresses vascu- lar angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation ,2000,101:594-597.
8Izawa H, Murohara T, Nagata K, et al. Mineralocorticoid receptor antago- nism ameliorates left ventricular diastolic dysfunction and myocardial fibro- sis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation ,2005,112:2940-2945.
